{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:45:37Z","timestamp":1793810737690,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nippon Boehringer Ingelheim Co. Ltd. and Eli Lilly and Company"},{"name":"AMED-CREST","award":["JP20gm1110012"],"award-info":[{"award-number":["JP20gm1110012"]}]},{"DOI":"10.13039\/501100020963","name":"Moonshot Research and Development Program","doi-asserted-by":"publisher","award":["21zf0127003s0201"],"award-info":[{"award-number":["21zf0127003s0201"]}],"id":[{"id":"10.13039\/501100020963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death with type 2 diabetes; however, their effect on arrhythmias is unclear. The purpose of this study was to investigate the effects of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 150 patients with type 2 diabetes who were treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator (ICD\/CRT-D) were randomized to once-daily empagliflozin or placebo for 24 weeks. The primary endpoint was the change in the number of ventricular arrhythmias from the 24 weeks before to the 24 weeks during treatment. Secondary endpoints included the change in the number of appropriate device discharges and other values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the empagliflozin group, the number of ventricular arrhythmias recorded by ICD\/CRT-D decreased by 1.69 during treatment compared to before treatment, while in the placebo group, the number increased by 1.79. The coefficient for the between-group difference was \u2212\u20091.07 (95% confidence interval [CI] \u2212\u20091.29 to \u2212\u20090.86;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The change in the number of appropriate device discharges during and before treatment was 0.06 in the empagliflozin group and 0.27 in the placebo group, with no significant difference between the groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.204). Empagliflozin was associated with an increase in blood ketones and hematocrit and a decrease in blood brain natriuretic peptide and body weight.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with type 2 diabetes treated with ICD\/CRT-D, empagliflozin reduces the number of ventricular arrhythmias compared with placebo.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      jRCTs031180120.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-024-02309-9","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T12:53:42Z","timestamp":1719579222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Shinya","family":"Fujiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingen","family":"Owada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morio","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tokano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kaneshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Maemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Niwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomio","family":"Umemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisako","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the EMPA ICD investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"issue":"11","key":"2309_CR1","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1253\/circj.CJ-20-1212","volume":"86","author":"K Ono","year":"2022","unstructured":"Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, Kusano K, Kobayashi Y, Koretsune Y, Sasano T, et al. JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. Circ J. 2022;86(11):1790\u2013924.","journal-title":"Circ J"},{"issue":"5","key":"2309_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","volume":"7","author":"International Hypoglycaemia Study Group","year":"2019","unstructured":"International Hypoglycaemia Study Group Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7(5):385\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2309_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00380-006-0962-9","volume":"22","author":"MR Movahed","year":"2007","unstructured":"Movahed MR, Hashemzadeh M, Jamal M. Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus. Heart Vessels. 2007;22(4):251\u20133.","journal-title":"Heart Vessels"},{"issue":"2","key":"2309_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ijcard.2014.08.105","volume":"177","author":"F Zaccardi","year":"2014","unstructured":"Zaccardi F, Khan H, Laukkanen JA. Diabetes mellitus and risk of sudden cardiac death: a systematic review and meta-analysis. Int J Cardiol. 2014;177(2):535\u20137.","journal-title":"Int J Cardiol"},{"issue":"22","key":"2309_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"2309_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, Group CPC. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"2309_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"2309_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"2309_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"2309_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"36","key":"2309_CR11","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","volume":"42","author":"JP Curtain","year":"2021","unstructured":"Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727\u201338.","journal-title":"Eur Heart J"},{"issue":"1","key":"2309_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","volume":"20","author":"HL Li","year":"2021","unstructured":"Li HL, Lip GYH, Feng Q, Fei Y, Tse YK, Wu MZ, Ren QW, Tse HF, Cheung BY, Yiu KH. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20(1):100.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2309_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/europace\/euab177","volume":"24","author":"D Sfairopoulos","year":"2022","unstructured":"Sfairopoulos D, Zhang N, Wang Y, Chen Z, Letsas KP, Tse G, Li G, Lip GYH, Liu T, Korantzopoulos P. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace. 2022;24(1):20\u201330.","journal-title":"Europace"},{"issue":"5","key":"2309_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/jce.15894","volume":"34","author":"CP Oates","year":"2023","unstructured":"Oates CP, Santos-Gallego CG, Smith A, Basyal B, Moss N, Kawamura I, Musikantow DR, Turagam MK, Miller MA, Whang W, et al. SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: meta-analysis of randomized clinical trials. J Cardiovasc Electrophysiol. 2023;34(5):1277\u201385.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"12","key":"2309_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372.","journal-title":"Nat Rev Cardiol"},{"key":"2309_CR16","doi-asserted-by":"crossref","unstructured":"Manolis AA, Manolis TA, Melita H, Manolis AS: Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias. Trends Cardiovasc Med 2023;33(7):418\u2013428.","DOI":"10.1016\/j.tcm.2022.04.003"},{"issue":"11","key":"2309_CR17","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/s13300-020-00924-9","volume":"11","author":"S Fujiki","year":"2020","unstructured":"Fujiki S, Iijima K, Okabe M, Niwano S, Tsujita K, Naito S, Ando K, Kusano K, Kato R, Nitta J, et al. Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in patients with type 2 diabetes (T2DM): Rationale and Design. Diabetes Ther. 2020;11(11):2739\u201355.","journal-title":"Diabetes Ther"},{"issue":"3","key":"2309_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","volume":"11","author":"E Araki","year":"2020","unstructured":"Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11(3):165\u2013223.","journal-title":"Diabetol Int"},{"issue":"5","key":"2309_CR19","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.2337\/db13-0468","volume":"63","author":"E Chow","year":"2014","unstructured":"Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, Sheridan PJ, Heller SR. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63(5):1738\u201347.","journal-title":"Diabetes"},{"issue":"18","key":"2309_CR20","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","volume":"373","author":"M Tancredi","year":"2015","unstructured":"Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"2309_CR21","doi-asserted-by":"publisher","first-page":"e011295","DOI":"10.1161\/JAHA.118.011295","volume":"8","author":"S Raghavan","year":"2019","unstructured":"Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K, Wilson PWF, Phillips LS. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8(4):e011295.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2309_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","volume":"19","author":"HY Chen","year":"2020","unstructured":"Chen HY, Huang JY, Siao WZ, Jong GP. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol. 2020;19(1):73.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2309_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","volume":"18","author":"GC Fernandes","year":"2021","unstructured":"Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, Myerburg RJ, Goldberger JJ. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098\u2013105.","journal-title":"Heart Rhythm"},{"key":"2309_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ahj.2022.01.008","volume":"246","author":"D von Lewinski","year":"2022","unstructured":"von Lewinski D, Tripolt NJ, Sourij H, Pferschy PN, Oulhaj A, Alber H, Gwechenberger M, Martinek M, Seidl S, Moertl D, et al. Ertugliflozin to reduce arrhythmic burden in ICD\/CRT patients (ERASe-trial): a phase III study. Am Heart J. 2022;246:152\u201360.","journal-title":"Am Heart J"},{"issue":"3","key":"2309_CR25","doi-asserted-by":"publisher","first-page":"e009156","DOI":"10.1161\/CIRCHEARTFAILURE.121.009156","volume":"15","author":"M Omar","year":"2022","unstructured":"Omar M, Jensen J, Burkhoff D, Frederiksen PH, Kistorp C, Videbaek L, Poulsen MK, Gustafsson F, Kober L, Borlaug BA, et al. Effect of empagliflozin on blood volume redistribution in patients with chronic heart failure and reduced ejection fraction: an analysis from the empire HF randomized clinical trial. Circ Heart Fail. 2022;15(3):e009156.","journal-title":"Circ Heart Fail"},{"issue":"17","key":"2309_CR26","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, Lamba S, Bhatt K, Brush J, Civitello A, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143(17):1673\u201386.","journal-title":"Circulation"},{"issue":"1","key":"2309_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tem.2013.09.002","volume":"25","author":"JC Newman","year":"2014","unstructured":"Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25(1):42\u201352.","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"2309_CR28","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14740\/jocmr2760w","volume":"8","author":"M Sano","year":"2016","unstructured":"Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016;8(12):844\u20137.","journal-title":"J Clin Med Res"},{"key":"2309_CR29","doi-asserted-by":"crossref","unstructured":"Mustroph J, Baier MJ, Pabel S, Stehle T, Trum M, Provaznik Z, Mohler PJ, Musa H, Hund TJ, Sossalla S et al: Empagliflozin Inhibits Cardiac Late Sodium Current by Ca\/Calmodulin-Dependent Kinase II. Circulation 2022;146(16):1259\u201361.","DOI":"10.1161\/CIRCULATIONAHA.122.057364"},{"key":"2309_CR30","doi-asserted-by":"crossref","unstructured":"Mustroph J, Wagemann O, Lucht CM, Trum M, Hammer KP, Sag CM, Lebek S, Tarnowski D, Reinders J, Perbellini F et al: Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail 2018;5(4):642\u201348.","DOI":"10.1002\/ehf2.12336"},{"key":"2309_CR31","doi-asserted-by":"crossref","unstructured":"Requena-Ibanez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, Atallah-Lajam F, Giannarelli C, Macaluso F, Lala A et al: Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study. JACC Heart Fail 2021;9(8):578\u201389.","DOI":"10.1016\/j.jchf.2021.04.014"},{"key":"2309_CR32","doi-asserted-by":"crossref","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, Picatoste B, Fardman B, Ishikawa K, Mazurek R, Pieper M, Sartori S, Rodriguez-Capitan J, Fuster V et al: Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction. Circ Cardiovasc Imaging 2023;16(4):e015298.","DOI":"10.1161\/CIRCIMAGING.123.015298"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02309-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T12:53:53Z","timestamp":1719579233000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02309-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2309"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02309-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by the Certified Review Board of the Niigata University Graduate School of Medicine and was performed in compliance with the Declaration of Helsinki and the Clinical Trials Act. All enrolled patients provided written informed consent prior to eligibility screening.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the submission of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.F. received funding support of present manuscript from Nippon Boehringer Ingelheim Co. Ltd, Eli Lilly and Company. Y.N. received grant and speaking honoraria from Nippon Boehringer Ingelheim. K.K. received honoraria for lectures from Medtronic, Boehringer-Ingelheim. Y.K. received speaking honoraria from Biotronik Japan, Boston Scientific Japan, Daiichi-Sankyo, Bayer Yakuhin, Abbott Medical Japan, Japan Lifeline, and received research grant from Daiichi-Sankyo. K.Tsujita received scholarship fund from Boehringer Ingelheim Japan. W.S. received grant from Nippon Boehringer Ingelheim, Daiichi Sankyo Company, Ltd., and received speaking honoraria from Nippon Boehringer Ingelheim, Daiichi Sankyo Company, Ltd.,Bristol-Meyers Squibb, Bayer Yakuhin, Pfizer, Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Johnson and Johnson KK, Medtronic Japan. H.T. received grant from Medtronic Japan Co., Ltd., Fukuda Denshi Kita-tohoku Hanbai Co., Ltd., BIOTRONIK Japan Co., Ltd., Japan Lifeline Co., and Boston Scientific Japan Co., Ltd., and received speaking honoraria from Boehringer Ingelheim. Masaya Watanabe received grant from Japan Society for the Promotion of Science and CASIO SCIENCE PROMOTION FOUNDATION. Masafumi Watanabe received grant from DAIICHI SANKYO COMPANY, LIMITED, CHUGAI PHARMACEUTICAL CO., LTD, Boston Scientific Corporation, Abbott Vascular Japan Co., Ltd, Cardinal Health, KANEKA MEDIX CORP, BIOTRONIK Japan, Inc, FUKUDA DENSHI, MEDTRONIC JAPAN CO., LTD, and received speaking honoraria from Otsuka Pharmaceutical Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Nippon Boehringer Ingelheim Co., Ltd. T.Murohara received from Japan Boehringer Inc., Ono Pharmaceutical Inc., Daiichi- Sankyo Inc., AstraZeneca Inc. T.Kato received honoraria for lectures from Boehringer-Ingelheim, AstraZeneca, Ono Pharmaceutical, Medtronic, BIOTRONIK, Boston Scientific, Abbott. K.M. received grant from Daiichi-Sankyo, and received honoraria for lectures from Daiichi-Sankyo, Novartis, Takeda, Pfizer, Nippon Boehlinger ingelheim. K.N. received speaking honoraria from Astellas, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, Novo Nordisk Pharma, Novartis Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, MSD. T.Minamino received funding support for the present study, provision of study drugs and remuneration for lectures from Nippon Boehringer Ingelheim and Eli Lilly. K.I., K.Takahashi, M.O., S.O., M.S., T.Tokano, T.Kaneshiro, H.H., S.N., T.U., H.Y., K.O., T.Tanaka, N.K. declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}